| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
Ethyl pyruvate is a carbonyl carboxylic acid. CTI-01 (ethyl pyruvate) is a novel anti-inflammatory drug used to treat severe inflammatory diseases. CTI-01 has shown potent anti-inflammatory and tissue-protective activity in various animal disease models, including pancreatitis, ischemia-reperfusion injury, sepsis, kidney injury, and endotoxemia. Ethyl pyruvate has been reported to be found in Zanthoxylum schinifolium, and relevant data exist. Drug Indications It has been studied for the treatment of burns and burn infections, cardiac surgery, inflammatory diseases (not specified), ischemia-reperfusion injury, and sepsis and septicemia. Mechanism of Action CTI-01 inhibits the systemic release of cytokines such as TNF-α and HMGB1, which promote the body's inflammatory response. Overexpression of these cytokines is associated with diseases occurring in intensive care settings, such as severe organ damage following cardiopulmonary bypass (CPB) and postoperative bowel obstruction following abdominal surgery.
|
| Exact Mass |
116.047
|
|---|---|
| CAS # |
617-35-6
|
| Related CAS # |
Ethyl pyruvate-d3;66966-38-9
|
| PubChem CID |
12041
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
155.0±0.0 °C at 760 mmHg
|
| Melting Point |
-58 °C
|
| Flash Point |
45 ºC
|
| Vapour Pressure |
3.1±0.2 mmHg at 25°C
|
| Index of Refraction |
1.399
|
| LogP |
0.05
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
8
|
| Complexity |
106
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XXRCUYVCPSWGCC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H8O3/c1-3-8-5(7)4(2)6/h3H2,1-2H3
|
| Chemical Name |
ethyl 2-oxopropanoate
|
| Synonyms |
CTI-01 CTI 01 CTI01
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~861.18 mM)
DMSO : ~100 mg/mL (~861.18 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01712295 | UNKNOWN STATUS | Drug: 17% Salicylate with ethyl pyruvate Drug: Salicylates |
Warts | Grossman, Michael, D.P.M. | 2011-11 | Phase 4 |
| NCT00107666 | TERMINATED | Drug: CTI-01 (ethyl pyruvate) | Coronary Disease Heart Valve Diseases |
Critical Therapeutics | 2005-04 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
